Home/Pipeline/GLP-1 MAP Program

GLP-1 MAP Program

Obesity / Type 2 Diabetes

Pre-clinicalActive

Key Facts

Indication

Obesity / Type 2 Diabetes

Phase

Pre-clinical

Status

Active

Company

Vaxess Technologies

About Vaxess Technologies

Terrestrial (Vaxess Technologies) is a private, clinical-stage biotech company pioneering a temperature-stable microarray patch (MAP) platform for transdermal drug delivery. Its core innovation involves dissolvable microneedles made from advanced biomaterials, which are designed to deliver a wide range of biologics and vaccines without the pain, sharps, or refrigeration requirements of traditional injections. The company is initially targeting the high-growth GLP-1 market and other large therapeutic areas, with a mission to make advanced therapies radically more convenient and accessible. Backed by venture capital and strategic partnerships, Terrestrial is advancing its platform through preclinical and clinical development.

View full company profile

Therapeutic Areas

Metabolic Diseases (e.g., Obesity, Diabetes)Infectious Disease (Vaccines)

Other Obesity / Type 2 Diabetes Drugs

Drug	Company	Phase	Status
REMD-477 (Volagidemab) + GLP-1	REMD Biotherapeutics	Phase 2 (planned)	Active